With tens of thousands of Americans anticipated to be diagnosed with multiple myeloma each year, it is essential for clinicians to remain informed about emerging clinical trial opportunities and the resulting data that may inform therapeutic strategies, affect clinical guidelines, expand treatment options, and ultimately improve patient quality of life.

Today, we have a selection of ongoing Phase 3 trials on multiple myeloma, currently recruiting in the United States. Patient eligibility varies by trial, with some trials seeking newly diagnosed patients, others seeking patients with relapsed or refractory myeloma, and others seeking patients who have received varying levels of treatment.

Featured Multiple Myeloma Clinical Trials
Study TitleEstimated EnrollmentStart DateEstimated Primary Completion
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)508February 2026August 2028
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant660January 2026January 2042
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma183January 2026September 2028
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)440March 2025December 2027
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) (DREAMM-10)520December 2024March 2031
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/​ Refractory Multiple Myeloma (iMMagine-3)450August 2024July 2028
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (MAGNETISMM-5)944October 2021April 2026
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)810September 2022January 2027
Phase 3 Multiple Myeloma Clinical Trials

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) (DURGA-4)

  • Sponsor: AstraZeneca
  • Goal: This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd [daratumumab, carfilzomib, and dexamethasone], DPd [daratumumab, pomalidomide, and dexamethasone], PVd [pomalidomide, bortezomib and dexamethasone], or Kd [carfilzomib and dexamethasone]) in participants with RRMM.
  • Interventions: AZD0120, daratumumab, carfilzomib, dexamethasone, bortezomib, pomalidomide
  • Primary Outcome Measures: To demonstrate the superiority of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of PFS in participants with RRMM; To demonstrate the superiority of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of MRD negativity rate at 9 months in participants with RRMM.
  • Time Frames: Three years; Two years.
  • Study Details
  • Source

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

  • Sponsor: AbbVie
  • Goal: This is a study to determine the adverse events, change in disease activity, and pharmacokinetics of etentamig in adult participants with multiple myeloma.
  • Interventions: Etentamig, lenalidomide, daratumumab, dexamethasone, dexamethasone
  • Primary Outcome Measures: Phase 2 and 3: Percentage of Participants with Adverse Events (AE)s; Phase 2: Change in Clinical Activity; Phase 3: Minimal Residual Disease (MRD) Negative CR Rate; Phase 3: Progression-Free Survival (PFS). 
  • Time Frames: Up to approximately 16 years; Up to approximately 52 weeks; Up to approximately 52 weeks; Up to approximately 130 months.
  • Study Details
  • Source

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

  • Sponsor: Takeda
  • Goal: The main aim of this study is to learn how well the Immune Globulin Infusion (human), 10 percentage (%) (IGI, 10%) can help prevent infections in participants with multiple myeloma receiving B-cell maturation antigen (BCMA) x cluster of differentiation 3 (CD3) directed bispecific antibody therapy.
  • Interventions: IGI, 10%
  • Primary Outcome Measure: Time to first serious infection.
  • Time Frame: Up to 12 months.
  • Study Details
  • Source

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

  • Sponsor: Juno Therapeutics, Inc. a Bristol-Myers Squibb Company
  • Goal: The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
  • Interventions: BMS-986393, cyclophosphamide, fludarabine, daratumumab, pomalidomide, dexamethasone, carfilzomib.
  • Primary Outcome Measure: Progression free survival (PFS); Minimal residual disease (MRD)-negativity in complete response (CR).
  • Time Frame: Up to five years after the last participant is randomized; Up to one year after the last participant is randomized. 
  • Study Details
  • Source

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) (DREAMM-10)

  • Sponsor: GlaxoSmithKline
  • Goal: The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.
  • Interventions: Belantamab mafodotin, lenalidomide, dexamethasone, daratumumab.
  • Primary Outcome Measures: PFS; Number of participants achieving MRD negative status.
  • Time Frame: Up to approximately seven years; Up to approximately seven years.
  • Study Details
  • Source

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/​ Refractory Multiple Myeloma (iMMagine-3)

  • Sponsor: Kite, a Gilead Company
  • Goal: The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug.
  • Interventions: Antiocabtagene autoleucel, cyclophosphamide, fludarabine, pomalidomide, bortezomib, dexamethasone, daratumumab, carfilzomib.
  • Primary Outcome Measures: Progression-free survival; Minimal residual disease complete response rate at nine months.
  • Time Frame: Up to four years; Up to nine months.
  • Study Details
  • Source

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)

  • Sponsor: Celgene
  • Goal: The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
  • Interventions: Mezigdomide, pomalidomide, bortezomib, dexamethasone
  • Primary Outcome Measure: Progression-free survival
  • Time Frame: From date of randomization to date of disease progression or death due to any cause (Up to approximately five years).
  • Study Details
  • Source

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (MAGNETISMM-5)

  • Sponsor: Pfizer
  • Goal: The purpose of this clinical trial is to learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone, and  learn about the safety and activity of elranatamab in combination with the anti-CD38 monoclonal antibody daratumumab. 
  • Interventions: Elranatamab, daratumumab, pomalidomide, dexamethasone.
  • Primary Outcome Measures: Safety Lead-In: Incidence of dose limiting toxicities; Randomized: Progression free survival per International Myeloma Working Group criteria; Frequency of treatment-emergent adverse events.
  • Time Frames: First 42 days after first elranatamab dose; From date of randomization to date of progressive disease, discontinuation from the study, death, or censoring, whichever occurs first, assessed up to 51 months; First 84 days after first elranatamab dose. 
  • Study Details
  • Source
Related Clinical Guidance:

Sign up for alerts and stay informed on the latest published guidelines.